Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Phase 1/2 Study of Ramucirumab Plus Nivolumab as Second-line Therapy in Participants With Gastric or GEJ Cancer

NCT02999295 is registered in ClinicalTrials.gov with National Cancer Center, Japan as lead sponsor.

NCT NCT02999295
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02999295 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Phase 1/2 Study of Ramucirumab Plus Nivolumab as Second-line Therapy in Participants With Gastric or GEJ Cancer
Lead sponsor
National Cancer Center, Japan
Phase
Phase 1/2
Overall status
Completed
Start date
January 31, 2017
Completion date
August 31, 2019
Enrollment
46 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer, gastroesophageal junction region (gej) cancer